Studies show promise for new drugs in lung, leukemia, ovarian cancers; some raise cost concern

Send to a friend

Send this article to a friend.

CHICAGO - For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy.

But the benefit in the study was so small — six extra weeks, on average — that it is raising fresh questions about the value of some costly new cancer medicines.

Eli Lilly and Co.'s drug Cyramza (sih-RAM-zuh) was tested in more than 1,200 patients. It is sold now for stomach cancer and costs $6,000 per infusion.

The study was discussed Saturday at a cancer conference in Chicago where doctors also reported progress with new drugs against relapsed ovarian cancer and chronic lymphocytic leukemia, the most common type of leukemia in adults.

Organizations: Eli Lilly and Co.

Geographic location: CHICAGO

  • 1
  • 2
  • 3
  • 4
  • 5

Thanks for voting!

Top of page

Comments

Comments